TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA approved Edwards Lifesciences’ Autus Size-Adjustable Valve for pediatric patients with congenital pulmonary valve disease. It can be implanted at about 13 millimeters and later expanded to as much as 22 millimeters; early study results were acceptable, while longer-term safety and performance remain under study.
The U.S. Food and Drug Administration on October 1, 2026, approved Edwards Lifesciences’ Autus Size-Adjustable Valve for pediatric patients with congenital pulmonary valve disease. The surgically implanted valve can be widened after implantation as a child grows, an approach that may reduce the need for repeat open-heart surgery, though the FDA says longer-term studies are still needed.
The valve can initially be implanted at about 13 millimeters in diameter, a size suited to some toddlers and preschool-aged children. Doctors can later widen it using a balloon catheter, with the device designed to reach as much as 22 millimeters, a size comparable to an adult pulmonary valve. The FDA describes it as the first heart valve designed to be expanded after surgery to accommodate a child’s growth.
The device also uses polymeric material for its leaflets, the flaps that open and close to regulate blood flow. The FDA said this is the first U.S.-approved valve to use polymeric leaflets for any indication; traditional valves use animal-derived tissue. The agency noted that animal-derived tissue can harden and break down sooner in children, while one-year follow-up data suggest the Autus valve’s synthetic leaflets have held up over time. That follow-up does not establish long-term durability.
The FDA based its decision on a clinical study that enrolled 62 pediatric patients at 12 U.S. sites. At six months, the first 60 patients had acceptable blood-flow performance, with no more than mild leakage through the valve. All patients had a successful procedure, and the study reported no deaths, strokes, blood clots requiring additional treatment or other clot-related complications. Three patients had a fracture in the valve frame, and two had reduced movement in a leaflet; neither issue caused symptoms in those patients.
How Expansion Could Change Valve Care
Children who need pulmonary valve replacement may outgrow an implanted valve. With conventional treatment, that can mean another operation to replace it. A valve that can be enlarged after implantation could give clinicians another way to respond as a child’s body grows, potentially reducing the number of repeat open-heart procedures for some patients and families.
The potential benefit does not mean every child will avoid further surgery. The FDA’s evidence comes from a relatively small study and early follow-up, and the agency said additional research is under way to assess longer-term risks and whether expansion can keep the valve functioning. For families and clinicians, the approval makes the device an available option; it does not settle how long it will last or which patients are best suited to receive it.
The device addresses a condition affecting a meaningful number of children. The FDA cited Centers for Disease Control and Prevention estimates that pulmonary valve atresia and stenosis together affect about 4,200 babies in the United States each year. Those figures describe the two conditions, not the number of children who will need this valve.
As an affiliate, we earn on qualifying purchases.
Why Children Need Pulmonary Valves
The pulmonary valve controls blood flow from the heart to the lungs. Congenital abnormalities can restrict that flow: pulmonary valve stenosis involves a narrowed valve, while pulmonary valve atresia means the valve does not form normally. The FDA says congenital heart defects overall affect about one in every 100 births in the United States.
Treatment for these defects can improve blood flow, but some children develop pulmonary regurgitation, in which blood leaks backward through the valve. Over time, significant leakage can weaken or enlarge the right ventricle and lead to valve replacement. Timing that intervention can be difficult: waiting may risk harm, while operating early may leave a child needing another procedure as they grow.
The Autus approval followed review through the FDA’s premarket approval pathway, which the agency describes as its most stringent route for medical devices. It is also the first pediatric approval from the FDA’s Total Product Life Cycle Advisory Program, a voluntary program intended to support device development. The FDA had previously granted the valve Breakthrough Device designation, which is intended to expedite development and review for certain devices.
“For far too long, children with congenital heart defects who need pulmonary valve replacement have had very limited surgical options, and those options have historically required multiple open-heart surgeries as children grow.”
— Kyle Diamantas, acting FDA commissioner
As an affiliate, we earn on qualifying purchases.
Long-Term Durability Remains Under Study
The available results do not yet show how the valve performs over many years or how often children will need another intervention. The FDA said longer-term studies are being conducted to better understand risks and gather evidence on whether expansion can maintain valve function and reduce procedures.
Some early findings warrant continued monitoring. Three study patients had valve-frame fractures and two had reduced leaflet movement, although none had symptoms from those events. Two patients whose valves began to deteriorate as they outgrew them had the devices successfully expanded without invasive surgery, according to the FDA; the agency cautioned that experience is limited. The source material does not specify the patients’ longer-term outcomes, the duration of planned follow-up, or how frequently the device should be checked after implantation.
expandable heart valve for children
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Follow-Up Will Test Lasting Performance
Longer-term studies will track how the valve and its leaflets perform, what risks arise as patients grow, and whether widening the device can preserve function over time. Those data will help clarify whether the early results translate into fewer operations for children treated with the valve.
For now, the FDA approval permits use for the indicated pediatric patients, with treatment decisions left to patients’ care teams. The next major evidence milestone is further follow-up from the clinical study and other longer-term monitoring; the FDA announcement did not give a date for those results.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the FDA approve?
The FDA approved Edwards Lifesciences’ Autus Size-Adjustable Valve, a surgically implanted pulmonary valve for pediatric patients with congenital pulmonary valve disease.
How does the valve accommodate a child’s growth?
It can be implanted at about 13 millimeters in diameter and later widened with a balloon catheter to as much as 22 millimeters. The FDA says the expansion is performed without invasive surgery, based on the limited study experience reported.
What did the clinical study find?
The study enrolled 62 children at 12 U.S. sites. At six months, the first 60 patients had acceptable blood-flow performance and no more than mild valve leakage. The study also recorded frame fractures and reduced leaflet movement in some patients, without symptoms from those events.
Does approval mean children will not need another operation?
No. The device may reduce the need for repeat open-heart surgery, but the FDA has not established that it will prevent further procedures. Longer-term studies are continuing, and the agency said experience with expansion remains limited.
Source: primary
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
